This article is part of the Research Topic The PML protein: a tumor suppressor and much more


Front. Oncol., 09 July 2013 |

Is PML a tumor suppressor?

  • Department of Experimental Oncology, European Institute of Oncology, Milan, Italy

The role of the promyelocytic leukemia (PML) protein has been widely tested in many different contexts, as attested by the hundreds of papers present in the literature. In most of these studies, PML is regarded as a tumor suppressor, a notion on the whole accepted by the scientific community. In this review, we examine how the concept of tumor-suppressor gene has evolved until now and then systematically assess whether this assumption for PML is supported by unambiguous experimental evidence.

Keywords: PML, tumor suppressor, cancer stem cells, cancer, cancer therapy

Citation: Mazza M and Pelicci PG (2013) Is PML a tumor suppressor? Front. Oncol. 3:174. doi: 10.3389/fonc.2013.00174

Received: 29 March 2013; Accepted: 20 June 2013;
Published online: 09 July 2013.

Edited by:

Paolo Pinton, University of Ferrara, Italy

Reviewed by:

Alexandre Arcaro, University of Bern, Switzerland
Michelangelo Campanella, Royal Veterinary College and University College London, UK

Copyright: © 2013 Mazza and Pelicci. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

*Correspondence: Pier Giuseppe Pelicci, Department of Experimental Oncology, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy e-mail: